Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Design Therapeutics Inc
(NQ:
DSGN
)
5.360
+0.470 (+9.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Design Therapeutics Inc
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
August 05, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
May 08, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
March 19, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
March 12, 2024
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
November 13, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
August 14, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
August 14, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
May 31, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
May 09, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
April 24, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
March 14, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics, Inc. (NASDAQ:DSGN) Investor Alert: Investigation Concerning Possible Wrongdoing
March 08, 2023
San Diego, CA -- (SBWIRE) -- 03/08/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Design Therapeutics, Inc.
Via
SBWire
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
February 08, 2023
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics, Inc. (NASDAQ:DSGN) Shareholder Notice: Investigation over Possible Violations of Securities Laws
January 19, 2023
San Diego, CA -- (SBWIRE) -- 01/19/2023 -- Design Therapeutics, Inc. is under investigation over potential securities laws violations.
Via
SBWire
DESIGN ALERT: Bragar Eagel & Squire, P.C. is Investigating Design Therapeutics, Inc. on Behalf of Design Stockholders and Encourages Investors to Contact the Firm
December 30, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
December 07, 2022
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
October 17, 2022
Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022
From
Design Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.